

Criteria 3.5.1

The number of MoUs, collaborations/linkages for Faculty exchange, Student exchange, Internship, Field trip, On-the-job training, research and other academic activities during the last five years

DVV Query

Provide e- copoies of MOU with Jehangir Centre for Learning, Pune, VEnsure Pvt Ltd, Mumbai, PharmaElite, Mumbai, Manipal Institute of Virology, Manipal for the year2021-22 along with dates of starting and completion year -wise signed by both parties.


DVV Clarifications

Item 3.5.1 of DVV response: Link is provided for the above MOUs signed by both the parties along with starting and completion date. Copies of MOUs are also attached.

S.No.	MOUs	Starting Date	Completion Date	Link for MOU
1	Jehangir Center for Learning, Pune	1st Feb 2021	31st Jan 2024	Jehangir-Center-for-Learning.pdf (indiraicp.edu.in)
2	VEnsure Pvt Ltd, Mumbai	1st July 2021	30th June 2024	V-Ensure-Pharma-Technologies-Pvt-Ltd.pdf (indiraicp.edu.in)
3	PharmaElite, Mumbai	1st Aug 2021	31st July 2024	Pharmaelite.pdf (indiraicp.edu.in)
4	Manipal Institute of Virology, Manipal	1st Apr 2022	31st March 2025	Manipal-Institute-of-Virology.pdf (indiraicp.edu.in)

MOU

Jehangir Center for Learning, Pune
And
SCES's Indira College of Pharmacy, Pune



1. MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding is made on 27th January, 2021 at between:

1. **Jehangir Center for Learning** - A division of Jehangir Clinical Development Centre (JCDC), a company incorporated under the provisions of the laws of India, with its registered office at 32 Sassoon Road, Pune 411 001, Maharashtra, India (hereinafter referred to as "JCL" which expression shall unless repugnant to the context or meaning thereof include its successors and permitted assigns) of the First Part

And

2. **Indira College of Pharmacy, Tathawade, Pune** having its registered office at 89/2A, Niramay, New Mumbai-Pune Highway, Tathawade, Pune 411033 (hereinafter referred to as Academic Partner & quote; Academic Partner which expression shall unless repugnant to the context or meaning thereof include its successors and permitted assigns) of the Second Part.

Singularly referred to as "the Party" and collectively referred to as "the Parties".

Whereas:

- a. "JCL", is the training division of JCDC established in January 2008 with a view to groom aspirants in the field of clinical research towards becoming the next generation of knowledgeable, ethical and professional leaders in this field. JCL offers e-learning courses in clinical research with a thorough emphasis on practical aspects the following are some of the highlights and unique features of the JCL course:
 - Experienced faculty (Our faculty consists of our leadership team with average work experience of at least 12+ years in clinical research). In addition to our own faculty, veterans from industry are invited as a visiting faculty.
 - Thorough grounding in principles viz. ICH GCP and ICMR guidelines and practical exposure in all aspects of conduct of a clinical trial.
 - Ideal foundation in Clinical Research.
- b. Academic Partner as a vision of creating academic excellence in the field of education. It fulfils the requirements of industry and society by holistically developing future performers having the right knowledge, skills and attitude towards profession.
- c. JCL and Academic Partner are keen to leverage mutual strengths on a non-exclusive basis; The Parties have thought it expedient to put forth the terms and conditions of collaboration in writing as hereinafter appearing.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.



PRINCIPAL
Indira College of Pharmacy
Tathawade, Pune - 411 033



NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS AND AGREEMENTS SET FORTH HEREIN AND FOR OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND SUFFICIENCY OF WHICH IS HEREBY ACKNOWLEDGED, THE PARTIES HERETO AGREE AS FOLLOWS.

2. ENGAGEMENT AND SCOPE OF THE AGREEMENT

- 2.1 This Agreement is the master agreement between the Parties. JCL hereby collaborates with Indira College of Pharmacy, Tathawade, Pune, on a non-exclusive basis for the purpose as mentioned hereinabove in the recitals. However, for the purpose of abundance of clarity, JCL reserves the right to enter into similar arrangements with any other Parties and Academic Partner agree that, Academic Partner shall in no manner whatsoever interfere with the same. Academic Partner further agrees that, Academic Partner shall in no manner whatsoever engage any other third parties for this purpose, without the prior written consent of JCL.
- 2.2 The main purpose of the Agreement is to foster collaboration between JCL and the Academic Partner, to provide opportunity for global experience to students, and facilitate advancement of knowledge in clinical research and various facets associated with it in terms of well-planned course modules.
- 2.3 JCL and Academic Partner will extend to each other the facilities and resources available with them through working out the necessary modalities from time to time and case-by-case for smooth conduct of the course.
- 2.4 JCL would conduct its e-learning courses and Post Graduate Diploma in Clinical Research (Online mode) in collaboration with the Academic Partner. This Memorandum of Agreement is signed by both Parties as per the mutually acceptable terms and conditions.

JCL'S RESPONSIBILITIES:

For e-learning course

The execution of the course will be JCL's responsibility. JCL would manage the day-to-day operations of the course. The following would be the responsibilities

- Generating the Log-in ID and Password on JCL's E-learning Portal after written confirmation is received from Academic Partner about completion of the admission of the student/s and after receiving the fees into JCL bank account.
- Conducting virtual doubt clearing sessions.
- Additional reading material shall be available on the E-Learning Portal.
- Conducting exams through the E-Learning Portal.

For Post Graduate Diploma in Clinical Research (Online Mode)

The execution of the course will be JCL's responsibility. JCL would manage the day-to-day operations of the course. The following would be the responsibilities

- Student Counseling
- Providing lecture schedule to the students on Academic Partner well in advance.
- Management of faculty.
- Conduct of lectures.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.



Myk



- Sharing online study material
- conducting test
- Fee collection
- Assistance in placement efforts in association with Academic Partner's placement cell.

ACADEMIC PARTNER'S RESPONSIBILITIES:

Academic Partner shall create awareness, market the course and provide logistic and infrastructure support such as:

For e-learning course

- Awareness creation, marketing of the course and enrollment of students into the course.
- Communicate and Coordinate with JCL for creation of user ID and Password for the enrolled students.

For Post Graduate Diploma in Clinical Research (Online Mode)

- Awareness creation, marketing of the course and enrollment of students into the course.
- Providing computer labs for attending online sessions, if required.
- Support for collection of fees. e.g. periodic reminders.

Both JCL and the Academic Partner will appoint one person as a single point of contact from each side. These individuals will communicate with each other on a regular basis to sort out administrative issues and review progress.

3. TERM

- 3.1 This Agreement shall continue for the period of three years from the date of signing of this Agreement until its termination in accordance with Clause 7. The Parties agree that the Agreement can be renewed by the Parties in writing mutually upon expiry or prior to the expiry of the term of the Agreement.

4. WORKING METHODOLOGY

4.1. Relationship Management

Academic Partner will designate one person as "Relationship Manager" to whom all pertinent communications within the purview of this Agreement will be addressed. In particular the "Relationship Manager" will be responsible for providing the assistance to JCL on all aspects of the relationship. JCL will in turn designate one of its employees or associates as its "Relationship Manager (JCL)". Any change in these designated personnel shall be agreed and intimated in writing to the parties from time to time.

4.2 Delivery Standards and Practices

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.



MY



JCL will deliver the course in accordance with the course structure design as decided by JCL and will circulate related study material to the students. JCL will also conduct the examination and evaluation thereof. The rights of alternation, modification in the course design and course material will be reserved by JCL.

4.3 Academic Partner will carry out the necessary promotional activities for the course wherein JCL staff will counsel the aspirants for the course.

4.4 JCL will provide a certification to the Students for the program after successful completion of the course by the students and passing the examination conducted by JCL.

5. FINANCIALS

5.1 Total Fees to students for a e-learning course in Professional Certification in Clinical Research (subject to revisions which may be applicable from time to time) -

- MRP of the course - Rs. 15,000 + Taxes (Currently Taxes are 18% GST)

5.2 Total Fees to students for Online live interactive batch for Post Graduate Diploma in Clinical Research (subject to revisions which may be applicable from time to time) -

- MRP of the course - Rs. 25,000 + Taxes (Currently Taxes are 18% GST)

6. INTELLECTUAL PROPERTY

6.1 The design of the course and the study material of the course will be the sole intellectual property of JCL. Appendix I defines design and modules covered and mutually agreed by both the Parties. Subject to the terms and conditions of this Agreement, the Parties agree that the Intellectual Property shall at all times, during the Term of this Agreement and thereafter be in the ownership, possession and control of JCL. The Parties agree that nothing in this Agreement shall be construed as granting any right, title or interest to Academic Partner, whether during the Term of this Agreement or thereafter. The Parties hereby agree that the JCL shall individually reserve the right to transfer, assign and convey this Intellectual Property. For the purpose of this Agreement, Intellectual Property includes without limitation ideas, concepts, creations, discoveries, inventions, improvements, know how, trade or business secrets, trademarks, service marks, designs, utility models, tools, devices, models, methods, procedures, processes, systems, principles, algorithms, works of authorship, flowcharts, drawings, books, papers, models, sketches, formulas, teaching techniques, electronic codes, proprietary techniques, research projects, and other confidential and proprietary information, computer programming code, databases, software programs, data, documents, instruction manuals, records, memoranda, notes, user guides; in either printed or machine-readable form, whether or not copyrightable or patentable, or any written or verbal instructions or comments; which is related to the business of the Parties. The Intellectual Property rights in and to the course including but not limited to the design, content, conduct, delivery, study material, notes, presentations, videos etc. solely rest JCL.

7. TERMINATION

7.1 Either party may terminate this Agreement forthwith on giving notice in writing to the other party if the other party:

- 7.1.1 commits any material breach of any term of this Agreement.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

- 7.1.2 shall convene any meeting of creditors or pass a resolution for winding up or suffer a petition for winding up;
- 7.1.3 shall have an administrative receiver or receiver appointed over the whole or part of its assets or suffer the appointment of an administrator;
- 7.1.4 If either Party acts in any manner which is prejudicial to the interests of the other Party;
- 7.1.5 If either Party indulges in any illegal or unlawful activity;
- 7.1.6 Misconduct, fraudulent, dishonest or undisciplined conduct of either Party, or breach of integrity, or embezzlement, or misappropriation or misuse or causing damage to the other Party's property;
- 7.1.7 misrepresentation and making of false statements and breaching the representations and warranties made under this Agreement;
- 7.1.8 the Academic Partner reserves the right to terminate this Agreement, if any third-party claims ownership of the Intellectual Property and sends a notice restraining the use of the same to JCL;
- 7.1.9 if either Party is declared insolvent or bankrupt.

7.2 Either Party may also terminate this agreement for convenience by giving the other Party 30 days' notice.

7.3 In either case of termination, Parties shall endeavor to ensure that the students complete the course they are pursuing.

7.4 On termination of this Agreement any sums owed by the defaulting Party to the other Party shall be paid forthwith to the other Party and if requested by the other Party shall return or if requested, destroy within seven calendar days of the date of termination all property belonging to that other Party. The defaulting Party shall certify in writing within 30 calendar days of termination to the other Party through a director or other officer of the company that the obligations imposed by this Clause have been complied with.

7.5 Termination of this Agreement howsoever caused shall not affect the rights of either Party under this Agreement which may have accrued up to the date of termination.

8. CONFIDENTIALITY

8.1 The Parties acknowledge that in the course of performing their obligations under this Agreement, the Parties may obtain information relating to the other Party which is of a confidential and proprietary nature to the other Party. The information which would be provided by either Party to the other Party shall be highly privileged and confidential in nature and either Party shall maintain strictest confidence with respect to such information provided by the other Party to the other Party from time to time.

8.2 Both Parties agree that it will (a) use such Confidential Information only in connection with fulfilling its obligations under this Agreement, (b) during the Term of this Agreement and thereafter, hold such Confidential Information in strict confidence and exercise due care with respect to its handling and protection of such Confidential Information, consistent with its own policies concerning protection of its own proprietary and/or trade secret information and (c) disclose, divulge or publish the same only to such of its employees or representatives in order for such employees or representatives to carry out the

Memorandum of Agreement between Jehangir Clinical Development Centre, JCL and Indira College of Pharmacy,
Tathawade, Pune.

purposes of this Agreement and to no other person or entity, whether for its own benefit or for the benefit of any other person or entity.

8.3 Both Parties further agree to return all Confidential Information in its possession, control or custody immediately upon termination or expiration of this Agreement.

8.4 Both Parties agree that in the event, either Party is required to disclose Confidential Information to any competent authority or under any applicable law, either Party shall intimate the other Party with regard to the disclosure of the Confidential Information and shall assist the other Party in obtaining a protective order. However, in the event of failure to obtain such an order, either Party shall disclose the Confidential Information to such competent authority. The Parties shall limit disclosure of the Confidential Information.

8.5 Either Party shall ensure that it shall in no manner whatsoever indulge in the disclosure or dissemination of Confidential Information to any third party with the prior written approval of the other Party. In the event of unauthorized disclosure and dissemination of Confidential Information by either Party to any third party, the same would cause irreparable injury to the other Party and no amount of monetary compensation would cure such an injury caused and such Party reserves the right to get an injunctive order from the court of competent jurisdiction preventing the other Party from making such unauthorized disclosures. Further, either Party reserves the right to immediately terminate the Agreement in the event of breach of the confidentiality obligation by the other Party.

8.6 For the purpose of this Agreement, Confidential Information means and includes, without limitation, any trade secrets, knowledge, data or other proprietary or confidential information relating to products, processes, know-how, intellectual property, designs, developmental or experimental work, ideas, innovations, computer programs, computer artwork, databases, other original works or authorship, customer and supplier lists, business plans, marketing plans and strategies, financial information or other subject matter pertaining to any business of the either Party or any of the either Party's customers, suppliers, consultants or licensees, which may or may not be registered under any of the laws pertaining to protection of intellectual property rights in the country; personnel data information and materials developed, collected or used by the personnel of either Party information related to deals or proposed deals to be entered into by either Party information disclosed by third parties with which either Party may have a business relationship, business practices and all other proprietary information, methods and property of either Party whether in tangible and/or intangible form.

9. REPRESENTATIONS AND WARRANTIES

9.1 Each of the Party represents and warrant that:

- 9.1.1 It has power to execute and enter into this Agreement and it has full right, capacity and authority to perform its obligations under this Agreement which when executed will constitute valid and binding obligations on it in accordance with its terms.
- 9.1.2 The entry and delivery of, and the performance by it of this Agreement will not result in any breach of any provision of applicable law, its constitutional documents, any other agreement and / or any court order, judgment, injunction, award, decree or writ that is binding on it and / or its assets, or result in any claim by a third party against the other Party;
- 9.1.3 The execution and delivery of this Agreement and the transactions contemplated hereby have been duly approved and authorized by all requisite actions and no other actions (corporate, statutory or otherwise) on its part are necessary.
- 9.1.4 It has understood the terms of this Agreement and a copy of the Agreement has been provided to it;

Memorandum of Agreement between Jehangir Clinical Development Centre's Ltd and Indira College of Pharmacy,
Tathawade, Pune.



- 9.1.5 It has executed this Agreement of its free will and without relying on any statements made by the other Party or its representatives, agents or affiliates etc.)
- 9.1.6 The Agreement in all respects is reasonable and necessary to protect the legitimate business interests of the Parties.

10. INDEMNIFICATION

- 10.1 Either Party hereby agrees to indemnify the other Party and each of its respective officers, employees, representatives attorneys, affiliates and agents and save and hold them harmless, from and in all respect of, including but not limited to all liabilities, obligations, damages, penalties, claims, actions, judgments, suits, fees, costs and expenses, including legal fees incurred in connection with or resulting from any claim, action or demand against them that arises out of or in any way relates to (i) any breach of any warranty or obligation under this Agreement; or (ii) negligence, fraud, misconduct or willful default on the part of the either Party during the term of this Agreement; (iii) any breach of any third party's rights; (iv) any breach of the terms and conditions of this Agreement.

11. NON-COMPETE

- 11.1 Academic Partner acknowledges and agrees that under no circumstances during the term of this Agreement and thereafter for a period of 3 years shall Academic Partner directly or indirectly compete with the business of JCL.

12. NON-SOLICITATION

- 12.1 Academic Partner covenant and undertake that Academic Partner shall not during the Term of this Agreement and for a period of [3.] years after the termination or expiry of this Agreement, directly or indirectly: (a) attempt in any manner to solicit any current clients/students of JCL or any firm, association or corporation or other entity which the JCL contacted or otherwise dealt business of the type carried on, or proposed to be carried on, by JCL; (b) attempt to persuade any person, firm or entity, which is a client/students (for the purpose of this Clause, client/students would also include potential client/students, where discussions have been held during the period of the JCL's engagement with Academic Partner with a view to conducting business with JCL to cease doing business or to reduce the amount of business which any such customer has customarily done or might propose doing with JCL whether or not the relationship between Parties and such client/students was originally established in whole or in part through its efforts; (c) employ, solicit, incite, canvass or attempt to employ or assist anyone else to employ any person who is in the employment/traineeship of JCL or was in the employment/traineeship of JCL at any time during the preceding 12 calendar months. Further, the Party shall not during such period solicit, incite or in any other way encourage other employees/trainees of JCL to terminate their respective contracts of employment/traineeship with JCL.

13. NOTICES

- 13.1 All notices which are required to be given hereunder shall be in writing and shall be sent to the address or by way of email of the recipient set out in this Agreement, or such other address as the recipient may designate by notice given in accordance with the provisions of this Clause. The addresses and email ids shall be as follows:

If to JCL:

Attention: Mr. Pathik Divate

Address: Jehangir Hospital Premises, 32 Sassan Road, Pune - 411 001.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

purposes of this Agreement and to no other person or entity, whether for its own benefit or for the benefit of any other person or entity.

8.3 Both Parties further agree to return all Confidential Information in its possession, control or custody immediately upon termination or expiration of this Agreement.

8.4 Both Parties agree that in the event, either Party is required to disclose Confidential Information to any competent authority or under any applicable law, either Party shall intimate the other Party with regard to the disclosure of the Confidential Information and shall assist the other Party in obtaining a protective order. However, in the event of failure to obtain such an order, either Party shall disclose the Confidential Information to such competent authority. The Parties shall limit disclosure of the Confidential Information.

8.5 Either Party shall ensure that it shall in no manner whatsoever indulge in the disclosure or dissemination of Confidential Information to any third party with the prior written approval of the other Party. In the event of unauthorized disclosure and dissemination of Confidential Information by either Party to any third party, the same would cause irreparable injury to the other Party and no amount of monetary compensation would cure such an injury caused and such Party reserves the right to get an injunctive order from the court of competent jurisdiction preventing the other Party from making such unauthorized disclosures. Further, either Party reserves the right to immediately terminate the Agreement in the event of breach of the confidentiality obligation by the other Party.

8.6 For the purpose of this Agreement, Confidential Information means and includes, without limitation, any trade secrets, knowledge, data or other proprietary or confidential information relating to products, processes, know-how, intellectual property, designs, developmental or experimental work, ideas, innovations, computer programs, computer artwork, databases, other original works or authorship, customer and supplier lists, business plans, marketing plans and strategies, financial information or other subject matter pertaining to any business of the either Party or any of the either Party's customers, suppliers, consultants or licensees, which may or may not be registered under any of the laws pertaining to protection of intellectual property rights in the country; personnel data information and materials developed, collected or used by the personnel of either Party information related to deals or proposed deals to be entered into by either Party information disclosed by third parties with which either Party may have a business relationship, business practices and all other proprietary information, methods and property of either Party whether in tangible and/or intangible form.

9. REPRESENTATIONS AND WARRANTIES

9.1 Each of the Party represents and warrant that:

- 9.1.1 It has power to execute and enter into this Agreement and it has full right, capacity and authority to perform its obligations under this Agreement which when exercised will constitute valid and binding obligations on it in accordance with its terms;
- 9.1.2 The entry and delivery of, and the performance by it of this Agreement will not result in any breach of any provision of applicable law, its constitutional documents, any other agreement and / or any court order, judgment, injunction, award, decree or writ that is binding on it and / or its assets, or result in any claim by a third party against the other Party;
- 9.1.3 The execution and delivery of this Agreement and the transactions contemplated hereby have been duly approved and authorized by all requisite actions and no other actions (corporate, statutory or otherwise) on its part are necessary;
- 9.1.4 It has understood the terms of this Agreement and a copy of the Agreement has been provided to it;

Memorandum of Agreement between Jehangir Clinical Development Centre (JCDC) and Indira College of Pharmacy,
Tathawade, Pune



Email id: pathik@jcdc.co.in

If to the Academic Partner:

Attention: Dr. (Mrs.) Anagha Joshi

Address: Indira College of Pharmacy, 89/2A, Nirmaya, New Mumbai – Pune Highway, Tathawade, Pune 411033.

Email id: ajoshi@indiraedu.com

13.2 Any such notice may be delivered by hand or by first class pre-paid letter or fax and shall be deemed to have been served if by hand when delivered, if by first-class post 48 hours after posting, and if by fax when confirmation of proper transmission has been received. If there is any change in addresses of either Party, the Parties shall intimate the same to the other Party within 7 (seven) days from the date of such change in the address.

14. HEADING

14.1 The headings to the Clauses of this Agreement are for ease of reference only and shall not affect the interpretation or construction of this Agreement.

15. DISPUTE RESOLUTION

15.1 All disputes, differences of opinion and controversies arising between the Parties out of this Agreement shall be resolved amicably, failing which they shall be finally settled by a sole arbitrator appointed by the Parties. The arbitration shall be conducted in accordance with the Arbitration and Conciliation Act, 1996 or any amendment thereof for the time being in force. Arbitration proceedings shall take place in Pune, India.

15.1.1 The award of the arbitrator shall be a reasoned award and shall be final and binding on the Parties. The arbitration proceedings shall be conducted and the award shall be rendered in English language.

15.1.2 During the pendency of any arbitration proceedings, the Parties shall continue to perform their respective obligations under this Agreement.

15.2 Subject to above, the Courts at Pune shall have exclusive jurisdiction in respect of all matters arising under or out of this Agreement.


16. ENTIRE AGREEMENT


16. This Agreement constitutes the entire agreement between the parties and the terms and conditions contained herein shall apply for the conduct of the course. No modification of these terms and conditions shall be effective unless accepted in writing and signed by duly authorized representatives of the Parties. This Agreement is in addition to the course structure and payment terms agreed by the Parties from time to time.

17. APPLICABLE LAW

17.1 This Agreement shall be governed by Indian law. The Pune courts will have non-exclusive jurisdiction to settle any disputes or claims which may arise out of or in connection with the Agreement for which purpose all parties agree to submit to such jurisdiction.

Memorandum of Agreement between Jehangir Chemical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.


PRINCIPAL
Indira College of Pharmacy
Tathawade, Pune - 411 033



18. EFFECTIVE DATE

18.1 This Agreement will be effective from 1st February, 2021.

19. AMENDMENT TO THE AGREEMENT

19.1 This Agreement shall not be amended, altered or modified, or any provision herein shall not be waived except by an instrument in writing expressly referring to this Agreement and signed by the duly authorized representatives of the Parties, and no verbal Agreement or conduct of any nature relating to the subject matter hereof or to the relationship between the Parties will be considered valid and enforceable.

20. ENFORCEABILITY OF AGREEMENT

20.1 If any part, or provision of this Agreement not being of a fundamental nature, is held illegal or unenforceable, the validity or enforceability of the remainder of this Agreement shall not be affected if such part, term or provision is severable from the rest of this Agreement without altering the essence of this Agreement. If such part, term or provision is not so severable, then the whole of this Agreement shall stand terminated, unless the Parties thereupon negotiate in good faith in order to agree to the terms of a mutually satisfactory provision, achieving as nearly as possible the same commercial effect, to be substituted for the provision so found to be invalid, illegal or unenforceable.

21. SURVIVABILITY

21.1 The terms of following Sections shall survive termination of this Agreement:

1. Intellectual Property (Clause 6),
2. Termination (Clause 7),
3. Confidential information (Clause 8),
4. Notices (Clause 13),
5. Survivability (Clause 21),
6. Indemnity (Clause 10)

22. FORCE MAJEURE


22.1 If either party is unable to perform its obligations or to enjoy the benefits of this Agreement because of any judicial Governmental decree, regulation or other direction not the fault of the Party who has been so affected, fire, flood, earth quake, failure of any satellite or other telecommunications link, civil unrest, terrorist attack or any natural disaster or Act of God (hereinafter referred to as the "Force Majeure Event") the Party who has been so affected shall immediately give notice to the other party and shall do everything possible to resume performance. Upon receipt of such notice, this Agreement thereby affected shall be suspended and, at its discretion, either Party may make arrangements to resume performance of the Agreement. If the period of non-performance exceeds 15 calendar days from the receipt of notice of the Force Majeure Event, unless arrangements for resumption of performance of the agreement have been made, the Party who has not been so affected may, by giving written notice, terminate this Agreement.

IN WITNESS WHEREOF, the parties have entered into this Agreement and do each hereby warrant and represent that their respective signatory whose signature appears below has been and is on the


Memorandum of Agreement between Jehangir Chitale Development Centre's JCL and Indira College of Pharmacy,
Tathawade, Pune.

Indira College of Pharmacy
Tathawade, Pune +91 932

date of this Agreement duly authorized by all necessary and appropriate corporate action to sign this Agreement.

Name: Mr. Patthik Divate
Title: CEO, JCDC
Sign: 
Date: _____

For and on behalf of Jehangir Center for Learning, Pune

Name: Dr. (Mrs.) Anagha Joshi
Title: Principal, Indira College of Pharmacy, Tathawade, Pune
Sign: 
Date: **PRINCIPAL**
Indira College of Pharmacy
Tathawade, Pune - 411 031

For and on behalf of Indira College of Pharmacy, Tathawade, Pune



Appendix I

Course Features:

(Professional Certification in Clinical Research)

1. Experienced faculty who are eminent members of Clinical research industry
2. Self-Paced course in E-learning format
3. 2-3 months Theory training (the time taken by every student can vary as it is self-paced online course)
4. Includes introduction to Clinical Data Management and Pharmacovigilance

Memorandum of Agreement between Jehangir Clinical Development Centre's JCDC and Indira College of Pharmacy, Tathawade, Pune



11

5. Includes Medical writing: Protocol development and CRF Design.

6. Periodic Doubt clearing sessions.

(Post Graduate Diploma in Clinical Research)

1. Experienced faculty who are eminent members of Clinical research industry.

2. Live interactive batch. (Using any e-meeting app)

3. 3-4 months theory training (online) (Weekend batch).

4. Includes introduction to Clinical Data Management and Pharmacovigilance

5. Includes Medical writing: Protocol development and CRF Design.

Course Content:

1. Introduction to Clinical Research.

2. Evolution of GCP.

3. Principles of GCP + Practical Application + Case Studies.

4. Phases of clinical trials and drug development process.

5. Medical Terminologies in Clinical Research.

6. Drug & Cosmetic Act 2019.

7. Informed Consent. Elements and Documentation.

8. Essential documents in clinical research.

9. Source Documentation.

10. Overview of Trial Design and Protocol Writing.

11. AE/SAE Reporting

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy,
Tathawade, Pune.

12. Fundamental of Clinical Data Management.

13. Fundamental of Pharmacovigilance.

Certification details:

1. JCL will be providing a certificate to all the students who complete our Clinical Research online training program. Certificate will mention: "Professional Certification in Clinical Research" from Jehangir Centre of Learning.
2. JCL will be providing a certificate to all the students who complete our Clinical Research online live training batch. Certificate will mention: "Post Graduate Diploma in Clinical Research" from Jehangir Centre of Learning.



Handwritten signature



Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy,
Tathawade, Pune.

MOU

V-Ensure Pharma Technologies Pvt Ltd, Mumbai
And
SCES's Indira College of Pharmacy, Pune

Date: 01/07/2021

**Memorandum of Understanding between V-Ensure Pharma Technologies Pvt Ltd,
and Indira College of Pharmacy**

V-Ensure Pharma Technologies Pvt Ltd, (V-Ensure) and SCES' Indira College of Pharmacy (ICP) hereby agree to enter into a Memorandum of Understanding (MoU) for academic and professional collaboration with the purpose of mutual benefit. ICP was established in 2006 and since then offers the courses of B. Pharmacy, M.Pharmacy, and Ph.D. V-Ensure has been in the business of pharmaceuticals for last 11 years. Both parties agree that giving exposure to the students to cutting edge technologies and practical projects will enable students to secure jobs as well as pursue entrepreneurship options. Both parties agree to the following terms

Internships and Placements and Corporate Relations:

- a. Both organizations will work closely to come up with models of regular engagement between ICP students and Faculties and V-Ensure trainers, developers and project managers.
- b. V-Ensure will offer training and internship to graduates and post-graduate students of ICP with a minimum stipend from commencement of the project, and as per their performance may offer placement.
- c. V-Ensure will conduct the placement drives at ICP to recruit fresh graduates and post-graduates at their R&D center and manufacturing plant.

Research:

- a. V-Ensure and ICP will work together on projects in areas of mutual interest. The projects will be executed partly at V-Ensure and partly in the college after approval of the research proposal by V-Ensure.
- b. The research work undertaken by V-Ensure will be published in reputed journals under the ownership of both the parties on approval from V-Ensure.
- c. V-Ensure will allow the students of ICP to use sophisticated instruments and equipment on a prior notice for the research work. This kind help extended by V-Ensure will be duly acknowledged by the students in their research publications and dissertation.

Industry Institute Partnership:

- a. ICP believes in inviting and involving Corporate Professionals for Board of Advisors, Guest Lectures, Workshops, Seminars and similar events for which expert/s are required for enhancing knowledge, skills and attitude of Faculty & Students. To achieve this objective, whenever possible, V-Ensure will allow their professional employees to visit ICP. ICP will also allow their faculty to visit V-Ensure for sharing their knowledge and expertise in the area of interest for V-Ensure.

Term of MOU:

This MOU shall be valid for a period of 3 years from the commencement date of 01/07/2021.

Contact Persons

Dr.(Mrs.) Madhur Kulkarni will be the contact person for ICP to initiate, manage or execute any joint activities between ICP and Pradeep Arya will be the contact person for V-Ensure.



By: Head HR - V-Ensure

Name:

PRADEEP ARYA



By: Principal - ICP

Name: Dr.(Mrs.) Anagha Joshi



Date: _____

Date: _____

NON-DISCLOSURE AGREEMENT

THIS NON-DISCLOSURE AGREEMENT (this "Agreement") is made and entered into as of 1st July 2021 between V-Ensure Pharma technologies Pvt Ltd., Navi Mumbai. (V-Ensure) and SCES's Indira College of Pharmacy, New Mumbai-Pune Highway, Tathwade, Pune, Maharashtra – 411033 (ICP) and Purpose: V-Ensure and ICP wish to explore Opportunities in Training, Student Corporate Placement, Research, & consultancy of mutual interest and in connection with this opportunity wishes to execute this Non-Disclosure Agreement ("NDA").

1. Confidential Information: Confidential information means any information disclosed to by one party to the other, either directly or indirectly in writing, orally or by inspection of tangible or intangible objects, including without limitation documents, business plans, source code, software, hardware, application and uses of hardware and software, documentation, financial analysis, marketing plans, customer names, customer list, customer data. Confidential Information may also include information disclosed to a party by third parties at the direction of a Disclosing Party. Confidential Information shall not, however, include any information which the Receiving party can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure; (ii) becomes publicly known and made generally available after disclosure through no action or inaction of Receiving Party; or (iii) is in the possession of Receiving Party, without confidentiality restrictions, at the time of disclosure by the Disclosing Party as shown by Receiving Party's files and records immediately prior to the time of disclosure. The party disclosing the Confidential Information shall be referred to as "Disclosing Party" in the Agreement and the party receiving the Confidential Information shall be referred to as "Receiving Party" in the Agreement.

2. Non-use and Non-disclosure: The Receiving Party agrees not to use any Confidential Information for any purpose except to evaluate and engage in discussions concerning a potential business relationship between the parties hereto. Receiving Party agrees not to disclose any Confidential Information to third parties or to its employees, except to those employees who are required to have the information in order to evaluate or engage in discussions concerning the contemplated business relationship. The Receiving Party shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the Disclosing Party's Confidential Information and which are provided to the Receiving Party hereunder.

3. Maintenance of Confidentiality Information: The Receiving Party agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information. Without limiting the foregoing, Receiving Party shall take at least those measures that Receiving Party takes to protect its own most highly confidential information and shall have its employees, if any, who have access to Confidential Information sign a non-use and non-disclosure agreement in content substantially similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. The Receiving Party shall not make any copies of Confidential Information unless the same are previously approved in writing by the Disclosing Party. The Receiving Party shall reproduce the Disclosing Party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original. The Receiving Party shall immediately notify the Disclosing Party in the event of any unauthorized use or disclosure of the Confidential Information.

4. No Obligation: Nothing herein shall obligate either party to proceed with any transaction between them, and each party reserve the right, in its sole discretion, to terminate the discussions contemplated by this Agreement concerning the business opportunity.

5. No Warranty: ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS", NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE.

6. Return of Materials: All documents and other tangible objects containing or representing Confidential Information and all copies thereof which are in the possession of Receiving Party shall be and remain the property of the Disclosing Party and shall be promptly returned to the Disclosing Party upon the Disclosing Party's request.

7. No License: Nothing in this Agreement is intended to grant any rights to either party under any patent, mask work right or copyright of Company, nor shall this Agreement grant Receiving Party any rights in or to Confidential Information except as expressly set forth herein.

8. Term: This Agreement shall survive for a period of 3 years from the date of disclosure of the Confidential Information.

9. Remedies: The Receiving Party agrees that any violation or threatened violation of this Agreement will cause irreparable injury to the Disclosing Party, entitling the Disclosing Party to obtain injunctive relief in addition to all legal remedies.

10. **Miscellaneous:** This Agreement shall bind and insure to the benefit of the parties hereto and their successors and assigns. This document contains the entire agreement between the parties with respect to the subject matter hereof. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. The parties have executed this Nondisclosure Agreement as of the date first above written.

[V-Ensure]

[ICP]

By: Head HR



Name: Mr. Pradeep Arya

Date: _____

By: Principal




Name: Dr. Anagha Joshi

Date: _____

MOU

PharmaElite, Mumbai
And
SCES's Indira College of Pharmacy, Pune



MEMORANDUM OF UNDERSTANDING (MOU)

This Memorandum of Understanding (hereinafter called as the 'MOU') is entered into on this 1st day of July 2021

BETWEEN

PHARMAELITE, a academy with its registered address at 3/Kishor Kunj, 2nd Floor, N.S. Mankikar Marg, Sion, Mumbai-400022 (Operating from Mumbai, Maharashtra) the First Party represented herein by its authorized signatory, CEO & Founder – Mr. Dharmesh Mehta (hereinafter referred as 'PHARMAELITE', the institution which expression, unless excluded by or repugnant to the subject or context shall include its successors – in-office, representatives, employees, administrators & assigns).

AND


SCES's Indira College of Pharmacy and represented herein by its authorized signatory and representative Dr. Anagha Joshi (hereinafter referred to as "Institution", company which expression, unless excluded by or repugnant to the subject or context shall include its successors – in – office, employees, representatives, administrators and assigns.)

(PHARMAELITE & INSTITUTION are hereinafter jointly referred to as – "PARTIES")

WHEREAS:

1. **PHARMAELITE ACADEMY** is **KNOWLEDGE PARTNER**: an expert in training & consulting – education services
2. Both parties, **PHARMAELITE & INSTITUTION**, believe that collaboration and co-operation between themselves will promote more effective use of each of their resources and provide each of them with enhanced opportunities.
3. Parties intent to co-operate and focus their efforts on co-operation within area of up-skilling via **WEBINARS, SEMINARS, CERTIFICATE COURSES**, Strategic consultation, Education and training programs.
4. Both Parties, being legal entities in themselves desire to sign this MOU for advancing their mutual interest;
5. The **INSTITUTION** is engaged in Education, Skill development, R&D services in the fields of Higher & Technical Education, Management & Professional Courses, Employability, Entrepreneurship Development and related fields

NOW THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES SET FORTH IN THIS MOU, THE PARTIES HERETO AGREE AS FOLLOWS:



CLAUSE 1: CO-OPERATION

- 1) Both Parties are united by common interests and objectives to empower youth/ students and they shall establish channels of communication and co-operation that will promote and advance their perspective operations within the Institutions and its related wings. The Parties shall keep each other informed of potential opportunities and shall share all non-confidential information that may be relevant to secure additional opportunities for one another. In case of exchange of confidential information being shared, the recipients(s) of such confidential information shall keep it protected like a reasonable and prudent man would for his own confidential information. Subject to a case-to-case basis prior written approval, INSTITUTION would arrange the logistics and pertinent operational expenses incurred for events/ interventions organized by INSTITUTION. It is recommended that INSTITUTION should use own infrastructure to reduce the operational expenses for any event (in-house) being hosted by INSTITUTION.
- 2) PHARMAELITE & INSTITUTION's co-operation will facilitate effective utilization of the subject matter expertise of PHARMAELITE & intellectual capabilities of students at INSTITUTION, providing significant inputs in developing suitable eco-systems, keeping in account needs of the INDUSTRY, to the INSTITUTION.
- 3) The general terms of co-operation shall be governed by this MOU. Both parties shall co-operate with each other and shall, as promptly as is reasonably and financially practical, and in order to encapsulate a case-to-case basis understanding of such financially practical cooperation enter into all relevant agreements, deeds and documents (the 'Definitive Documents') as may be required to give effect to the actions contemplated in terms of this MOU. The term of Definitive Documents shall be mutually decided between the parties. Along with the definitive documents, this MOU shall represent the entire understanding as to the subject matter hereof and shall supersede any prior understanding between the Parties on the subject matter hereof.

CLAUSE 2: SCOPE OF THE MOU

1. The budding graduates from INSTITUTION could play a key role in technological up-gradation, innovation and competitiveness of the industry. Both parties believe that close co-operation between the two would be of major benefit to the student community to enhance their skills and knowledge
2. PHARMAELITE will support in conducting various WEBINARS to train the students of INSTITUTION on skill-set according to Industry requirements including technical, professional and ethical skills to make them industry-ready
3. Internships and Placement support for students : PHARMAELITE will support in for INTERNSHIP & PLACEMENTS of STUDENTS of the INSTITUTION PARTY, if required
4. Faculty development programs : PHARMAELITE to train the faculties of the INSTITUTION for imparting industrial exposure/ training as per the Industrial requirement considering the National occupational standards in concerned sector, if available

[Signature]

[Signature]

5. Resource speaker/ person for Guest Lectures : PHARMAELITE to support in for GUEST LECTURES on various aspects like increasing technology, artificial intelligence, softwares, soft-skills, etc.
6. Research & development : Both parties may carry out the joint research activities in the field pertaining to the scope mentioned above.
7. Curriculum design: PHARMAELITE to support in for curriculum/ course design to guide in to help bridge the Industry-Academia GAP !!
8. Industrial training: Industry & institution interaction will give knowledge about latest updates/ developments in the PHARMACEUTICAL INDUSTRY. The Industrial sessions will help to prepare them for the increasing trends and further opportunities which industry holds in the future.
9. Parties to obtain internal approvals, consents, permissions and licenses of whatsoever nature required for offering the programs on terms specified herein
10. Expenses and commercials, if any, will be subjective to the nature and scope of engagement will be dealt separately

Both parties will decide on the nature of the intervention and commence once they mutually agree to it in writing prior to such intervention. In case of commercial activities, if any, BOTH PARTIES will have mutual consent on the commercial nature of the specific intervention and agree in writing (email, letter, notice, or any of other digital medium) before commencing any commercial/non-commercial engagement pertaining to the scope of the MOU.

CLAUSE 3: INTELLECTUAL PROPERTY

1. Nothing contained in this MOU shall, by express grant, implication, estoppel or otherwise, create in either party any right, title, interest or license in or to the intellectual property (including but not limited to know-how, inventions, patents, copyright and designs) of the other party
2. Both parties will respect each other privacy and IPR policies without any violation. In case of any violation of IPR, the MOU will be terminated immediately.

CLAUSE 4: VALIDITY

1. This agreement will be valid until it is expressly terminated by either Party on mutually agreed terms during August 2021 to August 2024 for a period of 3 years, PHARMAELITE and INSTITUTION, as the case may be, will take effective steps for implementation of this MOU. Any act on the part of KNOWLEDGE PARTNER, PHARMAELITE after termination of this agreement by the way of communication, correspondence, etc. shall not be construed as an extension of this MOU.
2. Both parties may terminate this MOU upon 30 calendar days notice in writing. In the event of termination, both parties have to discharge their obligations.

CLAUSE 5: RELATIONSHIP BETWEEN THE PARTIES



1. Any divergence or difference derived from the interpretation or application of the MOU shall be resolved by arbitration between the parties as per the Arbitration Act, 1996. The place of the arbitration shall be at HEAD OFFICE of Indira College of Pharmacy.

This undertaking is to be constructed in accordance with Indian Law with exclusive jurisdiction in the courts of Mumbai.

2. It is expressly agreed that PHARMAELITE and INSTITUTION are acting under this MOU as Independent contractors, and the relationship established under this MOU shall not be construed as a partnership. Neither party is authorized to use the other Party's name in any way to make any representations or create any obligation or liability, expressed or implied, on behalf of the other party, without the prior written consent of the other party. Neither party shall leave, nor represent itself as having, any authority under terms of this MOU to make agreements of any kind in the name of or binding upon the other party to pledge the other party's credit, or to extend credit on behalf of other party.

AGREED BY:

For First Party:

For Second Party:

Mr. Dharmesh Mehta, CEO

Authorized Signatory (Name and Sign)

Authorized Signatory (Name and Sign)

PHARMAELITE	SCES's Indira College of Pharmacy
Maharashtra (IND)	Maharashtra
+91-9082087537/ +91-8433830815	+91- 9326003747
pharmaelite17@gmail.com	anagha.joshi@indiraicp.edu.in
hr@pharmaelite17.com	adminicp@indiraicp.edu.in
dharmeshniperhyd@gmail.com	
www.pharmaelite17.com	www.Indiraicp.edu.in

Seal/ Stamp:

First Party:

Second Party:



MOU

Manipal Institute of Virology, Manipal
And
SCES's Indira College of Pharmacy, Pune

This MEMORANDUM OF UNDERSTANDING (hereinafter referred to as "AGREEMENT") is made and entered into as on the 15th day of March, 2022 and deemed to be effective from 1st day of APRIL, 2022 ("EFFECTIVE DATE") by and between:

Manipal Academy of Higher Education (MAHE), a deemed to be University under Section 3 of UGC Act, 1956, having its registered office at Madhav Nagar, Manipal – 576104, Karnataka, India, on behalf of **Manipal Institute of Virology** (hereinafter referred to as "**MIV**"), a constituent unit of MAHE, and represented by its Registrar, Dr. Narayana Sabhahit, hereinafter referred to as the **FIRST PARTY**

AND

SCES's Indira College of Pharmacy (ICP), established under the aegis of Savitribai Phule Pune University, having its office at Ganeshkhind Pune, Maharashtra 411007 and represented by its **Principal, Dr. Anagha Joshi** hereinafter referred to as the **SECOND PARTY**

Whereas –

- A. MIV, a constituent unit of the First Party, is a center for training, education and research in virology with the state-of-the-art laboratory. Antiviral testing services is a platform to support the research related activities of interested academic and industrial collaborators.
- B. Both parties wish to enter into an Agreement wherein the First Party, through its constituent unit MIV, shall provide testing facility on a nominally charged basis for the assessment of *in vitro* cytotoxicity and *in vitro* antiviral activity of the test samples provided by the Second Party. These charges are mainly towards the cost of consumables, required for the execution of the experiments involved.
- C. Both parties are higher education institutions with full legal capacity to establish commitments, and whose mission includes providing quality learning opportunities for its students and communities, as well as promoting academic research;
- D. Both parties having the facility and objective to undertake research activity, have the required infrastructure, personnel and research minded employees with right aptitude,
- E. Both the institutions have agreed to carry out research projects with special emphasis on antiviral drug discovery and development.

Now, Therefore, in consideration of mutual agreements, covenants, representations and warranties set forth in this Agreement, the Parties hereby agree to the following clauses,



- 1) The Commencement Date of this Agreement shall be 1st day of APRIL, 2022. This Agreement shall be valid for a period of 3 (three) years from the Commencement Date.
- 2) This agreement shall establish the criteria under which MAHE and ICP will carry out joint collaborative activities of mutual interests, particularly in the field of antiviral drug discovery and development to improve quality of research and build the capabilities of their students and faculty members.
- 3) Both the parties agree to share their expertise for academic and research collaborations of mutual interests.
- 4) The parties may, jointly or separately, endeavor to obtain financial resources from other institutions, government agencies and national and international organizations for the development of activities associated with the implementation of any Specific Agreement.
- 5) Both parties agree that any of the laws and rules laid down by MAHE, ICP, State Government, Central Government, UGC and appropriate regulatory authorities will be strictly adhered to and its change that may occur time to time in future are followed.
- 6) The parties shall perform the research studies in compliance with (i) the Agreement (ii) the drafted Protocols, (iii) approval of institutional review board / institutional ethics committee (IEC), and (iv) generally accepted laboratory and pharmacological practices as recommended in their latest guidelines of Institutional Bio-Safety committee (IBSC), Department of Biotechnology-India (DBT) and Indian Council of Medical research (ICMR, MoHFW, Govt. of India)
- 7) Both the parties share the rights to use the data and results generated from their collaborative study; for their internal research, educational (including teaching) purposes, publication and/or presentation in any reputed journal and/or conference, patents with receiving due acknowledgment from the other Party.
- 8) Both the parties agree to publish the results irrespective of whether it is positive or negative and that they include each other's name with prior consent from the other party.
- 9) The parties agree to maintain the confidentiality on information related to the co-operative activities such as financial, scientific, corporate, industrial, product and business information disclosed by the other Party and/or its Affiliates and any and all results, information, data and documents generated, produced or obtained.
- 10) The list of antiviral screening tests with respective codes and charges is enclosed (Please refer **Annexure A**). The rate list shall be valid for 1 (one) year from the date of commencement and 18% GST shall be charged EXTRA by MAHE as per the prevailing tax norms.
- 11) If the Second Party agrees to include the First Party as co-authors in any related scientific publications or share the rights of any intellectual property generating out of this work, a discounted rate as mentioned in Annexure A, may be applied to cover only the working costs involved.



- 12) The test samples shall be packed and dispatched by the Second Party and collected by the First Party. The First Party shall not be responsible for any damage or loss of the test samples caused due to oversight/negligence during dispatch or in transit. The responsibility to pack and dispatch the samples on time, shall lie with the Second Party.
- 13) The budget for the experimental expenditures will be prepared by the First Party depending on the number of test samples requested for antiviral testing by the Second Party.
- 14) Billing shall be done by the First Party and a statement/Invoice for payment, once ready will be sent to the Second Party. Payments shall be made within **10 days** of receipt of the statement.
- 15) Depending upon the standard testing procedure and time required for performing the test, the First Party shall send the reports of the test samples by email to the Second Party.
- 16) The First Party shall not be responsible for any delays resulting from infrastructural break down or any other specific issues that prevent from undertaking the test which are out of control of the management of the First Party.
- 17) The First Party shall be conducting all the tests following standardized laboratory protocols and will be responsible for the authenticity of the test results. In case of any disagreements from the Second Party regarding outcome of the results obtained, the First Party should not be held responsible.
- 18) The present Agreement will become valid upon signature by both parties and shall remain in effect for a period of three years from its effective date. The agreement may be amended at any time by a written agreement signed by authorized representatives of both parties.
- 19) **Termination of the Agreement:** Termination of the Agreement may be effected by a notice, in writing, **1 (one) month** prior, by either Party. If the Second Party wishes to terminate the Agreement, they shall inform the First Party in writing, about the intention to discontinue the Agreement and clear all outstanding amount. However, in any circumstances the paid amount shall not be refunded.
- 20) In case of continuance of the collaborative work, after completion of the term of the Agreement, a renewal for extension is mandatory.
- 21) This Agreement shall be governed by Indian Laws and in case of any disputes, it shall be resolved amicably by the Parties, primarily through mediation between the Chief Executives of the two organizations.



In Witness Whereof, each Party to this Agreement has caused it to be executed by its duly authorized representative as of the Commencement Date.

For and on behalf of

Manipal Academy of Higher Education,
Manipal





Name: Dr. Narayana Sabhahit
Title: Registrar

For and on behalf of


Indira College of Pharmacy
Pune



Name: Dr. Anagha Joshi
Title: Principal

For and on behalf of


Manipal Institute of Virology, Manipal



Name: Dr. Chiranjay Mukhopadhyaya
Title: Director, MIV, MAHE

For and on behalf of

Indira College of Pharmacy, Pune



Name: Dr. Madhur Kulkarni
Title: Associate Professor
& HOD- Pharmaceutics

ANNEXURE A
CYTOTOXICITY/ANTIVIRAL SCREENING PANEL

RATE LIST FOR ACADEMIC COLLABORATORS			
CODE	CATEGORY & TEST	PRICE (INR)	DISCOUNTED PRICE (INR)
VIRS008	Cytotoxicity assessment per test sample per cell line	5000	3000
VIRS009	Antiviral screening against Herpes simplex virus 1- post-infection treatment with each test sample	10000	6000
VIRS010	Antiviral screening against Herpes simplex virus 1- pre-infection treatment with each test sample	10000	6000
VIRS011	Antiviral screening against Herpes simplex virus 1- simultaneous treatment with each test sample	10000	6000
VIRS012	Antiviral screening against Herpes simplex virus 2- post-infection treatment with each test sample	10000	6000
VIRS013	Antiviral screening against Herpes simplex virus 2- pre-infection treatment with each test sample	10000	6000
VIRS014	Antiviral screening against Herpes simplex virus 2- simultaneous treatment with each test sample	10000	6000
VIRS015	Antiviral screening against Influenza A(H1N1) pdm09 virus- post-infection treatment with each test sample	10000	6000
VIRS016	Antiviral screening against Influenza A(H1N1) pdm09 virus- pre-infection treatment with each test sample	10000	6000
VIRS017	Antiviral screening against Influenza A(H1N1) pdm09 virus- simultaneous treatment with each test sample	10000	6000

